Evidence map›Paper›PMID 39796128›Full record

ArticleInternational journal of molecular sciences2024

Effects of Antioxidant Amino Acids on Cancer Sarcopenia.

Shota Nukaga, Rina Fujiwara-Tani, Takuya Mori, Isao Kawahara, Ryoichi Nishida, Yoshihiro Miyagawa, Kei Goto, Hitoshi Ohmori, Kiyomu Fujii, Takamitsu Sasaki and 5 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shota NukagaDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.
Rina Fujiwara-TaniDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.
Takuya MoriDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.ORCID 0000-0001-7004-7179
Isao KawaharaDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.
Ryoichi NishidaDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.ORCID 0009-0008-6517-8420
Yoshihiro MiyagawaDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.
Kei GotoDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.
Hitoshi OhmoriDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.
Kiyomu FujiiDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.
Takamitsu SasakiDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.
Chie NakashimaDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.
Yi LuoDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.
Shingo KishiDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.
Ruiko OgataDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.
Hiroki KuniyasuDepartment of Molecular Pathology, Nara Medical University School of Medicine, Kashihara 634-8521, Japan.ORCID 0000-0003-2298-8825

Funding

Ministry of Education, Culture, Sports, Science and Technology 19K16564Ministry of Education, Culture, Sports, Science and Technology 20K21659Ministry of Education, Culture, Sports, Science and Technology 21K06926Ministry of Education, Culture, Sports, Science and Technology 22K11423Ministry of Education, Culture, Sports, Science and Technology 23K16547Ministry of Education, Culture, Sports, Science and Technology 23K19900
6 · The paper itself

Abstract

Cancer sarcopenia is highly prevalent in patients with advanced cancer, which is closely related to the disease prognosis. Overcoming cancer sarcopenia is important for cancer treatment. Cystine and theanine (CT), antioxidant amino acids, have been applied to the nutritional intervention of various diseases but their effects remain unclear on cancer sarcopenia. We attempt to examine the effect of CT on cancer sarcopenia. Both mouse and in vitro cachexia models showed that CT reduced oxidative stress, inhibited autophagy and apoptosis, improved oxidative phosphorylation and the suppression of high mobility group box-1 production, and improved sarcopenia and muscle maturity. When treated with 5-fluorouracil in a mouse cachexia model, tumor weight decreased but oxidative stress increased and muscle weight and muscle maturity were suppressed regardless of diet. However, in the CT group, oxidative stress was reduced and the exacerbation of sarcopenia by 5-fluorouracil was suppressed. Thus, in cancer cachexia, oxidative stress plays a major role in skeletal muscle damage, and CT, which has an anti-oxidative stress effect, has a strong protective effect on skeletal muscle. In the future, it will be important to conduct clinical studies on nutritional intervention for cancer sarcopenia using CT.

Indexed as

Amino AcidsAntioxidantsNeoplasmsSarcopeniaAnimalsApoptosisAutophagyCachexiaCell Line, TumorDisease Models, AnimalFluorouracilHumansMaleMiceMuscle, SkeletalOxidative StressAmino AcidsAntioxidantsFluorouracilBCAAcancer sarcopeniacystinemetabolismtheanine

Identifiers

PMID39796128
PMCPMC11720704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.